Skip to main content

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Projects

Aplicación de la tecnología de secuenciación masiva para optimizar el coste-efectividad del tratamiento de la hepatitis C (VHC) en la era de los inhibidores de acción directa (DAAs).

IP: Juan Ignacio Esteban Mur
Collaborators: Lluís Viladomiu Catà, Lluis Castells Fusté, Josep Quer Sivila, Damir Garcia Cehic, Cristina Dopazo Taboada
Funding agency: Instituto de Salud Carlos III
Funding: 192692.5
Reference: PI13/00456
Duration: 01/01/2014 - 31/01/2017

Complejidad de la cuasiespecie del virus de la Hepatitis B en las regiones X, precore y core: Asociación con la severidad de la infección

IP: -
Collaborators: Clara Ramírez Serra, Lluis Castells Fusté, Silvia Camòs Anguila, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 98373
Reference: PI12/01893
Duration: 01/01/2013 - 31/03/2016

Expansión/restauración funcional de células CD4 NS3 específicas autólogas en la prevención de la recurrencia VHC post-trasplante hepático: optimización del proceso para uso clínico

IP: Juan Ignacio Esteban Mur
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Silvia Sauleda Oliveras, Isabel Campos Varela, Marta Bes Maijo, Maria Madeleine Piron
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI10/01505
Duration: 01/01/2011 - 30/06/2014

Estudio dinámico de quasispecies de VHC por pirosecuenciación en fase aguda y crónica durante tratamiento antiviral (PIROVIRUSC)

IP: Josep Quer Sivila
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 121000
Reference: SAF2009-10403
Duration: 01/01/2010 - 31/12/2012

Ministerio de Ciencia

Related news

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Jaume Alijotas Reig

Jaume Alijotas Reig

Head of group
Systemic Diseases
Read more
Guillem Pons Barcons

Guillem Pons Barcons

Postdoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Javier Sánchez López

Javier Sánchez López

Research technician
Research Group on Status Epilepticus and Acute Seizures
Read more
Rafael Simó Canonge

Rafael Simó Canonge

Head of group
Diabetes and Metabolism
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.